Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $109.79M | $-153.49M | $-3.19 |
| 2024 | $90.40M | $-126.87M | $-2.96 |
| 2023 | $82.71M | $-102.24M | $-3.55 |
| 2022 | $64.36M | $-109.78M | $-4.79 |
| 2021 | $48.04M | $-110.82M | $-4.96 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $0.10 per share
Typical surprise -5.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.28 vs $-0.27miss
- Wed, May 6$-0.47 vs $-0.56beat
- Mon, Mar 2$-0.54 vs $-0.52miss
- Thu, Nov 6$-0.69 vs $-0.72beat
- Thu, Aug 7$-1.05 vs $-0.82miss
- Mon, May 12$-0.92 vs $-0.83miss
Estimates and results for URGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
URGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newszacks.com·1d ago·Neutral
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗